Canada — Health Canada & Optimi Health

Canada — Health Canada: Canada — Health Canada's regulation of ibogaine under the Food and Drugs Act and its listing on the Prescription Drug List provides a favorable regulatory environment for Optimi Health's operations.

Optimi Health: Optimi Health has secured ibogaine supply and is commencing development of finished drug products, positioning itself as a key supplier in the emerging psychedelic therapy market.

Canada — Health Canada: Canada — Health Canada issued the Drug Establishment Licence (DEL) to Optimi Health, authorizing the company's manufacturing, packaging, labeling, testing, storage, and distribution of controlled drug products.

Optimi Health: Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial, expanding its international market reach and solidifying its position as a vertically integrated GMP supplier of psychedelic drug products. It also completed a GMP production run of 5mg psilocybin capsules, with some earmarked for clinical research in the United States and Europe.

Canada — Health Canada: Canada — Health Canada has issued a Drug Establishment License (DEL) to Optimi Health Corp., allowing it to produce and distribute regulated psychedelic drug products.

Optimi Health: Optimi Health Corp. has launched new microdose psilocybin products, expanding its product range and market reach for clinical research and therapeutic programs internationally. This development is expected to positively impact the company's revenue and market position.

Canada — Health Canada: Canada — Health Canada issued the Drug Establishment Licence for Optimi Health's facility and the export authorization for the psilocybin shipment to Australia, regulating the production and export of these controlled substances.

Optimi Health: Optimi Health completed its third commercial shipment of psilocybin to Australia, expanding its market presence and generating recurring revenue from the sale of its psychedelic drug products for medical use.

Optimi Health: Optimi Health completed the first 2026 production and export of MDMA and psilocybin capsules to Australia, expanding its market access for psychedelic treatments for PTSD and TRD.